Moderna Secures $50M CEPI Funding to Advance Ebola Vaccine Candidate
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna has expanded its collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), securing up to $50 million in funding. This capital will support preclinical development and Phase 1 clinical testing for a potential vaccine against Bundibugyo ebolavirus, a disease currently experiencing a Public Health Emergency of International Concern. This non-dilutive funding helps advance Moderna's infectious disease pipeline, leveraging its mRNA platform for a vaccine where none are currently licensed. Phase 1 safety and immunogenicity data will be critical for the program's progression to larger trials.
At the time of this announcement, MRNA was trading at $47.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.7B. The 52-week trading range was $22.28 to $59.55. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.